Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same

An adipocyte and matrix technology, applied in cell culture medium, biochemical equipment and methods, tissue culture, etc., can solve problems such as difficulty in evaluating efficacy, dosage, stem cell host immune system attack, etc., and achieve the effect of storage stability

Pending Publication Date: 2018-12-21
CELL CARE THERAPEUTICS INC
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Implanted stem cells are also vulnerable to the host immune system, and it is often difficult to assess potency and / or control "dosing administered"

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
  • Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
  • Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0216]Example 1. Development of adipose tissue-derived mesenchymal stromal cell conditioned medium product under cGMP guidelines

[0217] Manufacturing plan

[0218] Donor selection and tissue harvest

[0219] About 150-300ml of abdominal tissue extracted by liposuction can be selected from suitable donors (such as non-smoking women under the age of 30, with a family history of longevity on both sides of the family, and / or without known diseases or chronic diseases Significant family history.

[0220] Digestion

[0221] Adipose tissue digestion was accomplished using minor modifications to standard tissue digestion protocols known in the art. Preferably, these changes are changes that help increase the overall POASC yield.

[0222] Approximately 300 ml of lipoaspirate was transferred to a sterile bottle with the adipose tissue above the blood fraction. Remove blood from beneath the adipose tissue using a 10 ml aspirator pipette and rinse the lipoaspirate with 300 ml DPB...

Embodiment 2

[0333] Embodiment 2: the preparation and testing of the pharmaceutical composition comprising lyophilized composition and slow-release drug delivery matrix

[0334] A 2 ml solution of the lyophilized composition prepared as outlined in Example 1 at a protein concentration of approximately 400 micrograms / ml was prepared and used as the starting solution for incorporation into the sustained release delivery matrix.

[0335] Macro matrices were formulated and release profiles were measured from six different matrices. An overview of the matrix is ​​shown in the table below:

[0336]

[0337] Figure 10 Preliminary release data (expressed as percent payload) showing burst and 90-day release measurement points. The observed burst and steady release measurements were as expected.

Embodiment 3

[0338] Embodiment 3: the in vivo tolerance test of lyophilized composition

[0339] This study was designed to evaluate the ocular tolerance of CC-101 in non-human primates following intravitreal (IVT) injection to establish doses for efficacy testing. This was achieved by slit-lamp examination, retinal imaging, tonometry, and clinicopathology after repeated escalation administrations.

[0340] Test Compound Disposal

[0341] During the two-day shipping transit time, the vials were kept on dry ice in a shipping container kept below -20 °C. Vials were then kept at -20°C until thawed at room temperature immediately prior to use. At the time of dosing, a low dose (64 μg / ml) was prepared by adding 1 mL of 0.9% sterile saline to a 5 mL vial of 15CCT1-150709 CC-101 Histidine. The high dose (128 μg / ml) was prepared by adding 0.5 mL of 0.9% sterile saline to a 5 mL vial of 15CCT1-150709 CC-101 histidine.

[0342] Subject recruitment

[0343] Three adult males who performed the ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are lyophilized compositions containing the secretome of cultured adipose cells, pharmaceutical compositions that additionally contain a sustained release drug delivery matrix, as wellas methods of making and using such compositions.

Description

[0001] related application [0002] This application claims priority to US Provisional Application No. 62 / 294,489, filed February 12, 2016, and US Provisional Application No. 62 / 414,285, filed October 28, 2016, each of which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates generally to compositions comprising secretions of stem cells derived from conditioned media and methods of making and using them. Background technique [0004] Regenerative medicine is the field of medicine concerned with the replacement or regeneration of human cells, tissues or organs in order to restore or establish normal function. For example, stem cell therapy can be used to treat, prevent or cure various diseases and disorders. [0005] Stem cells are cells that have the ability to divide indefinitely and, under certain conditions, can differentiate into many different cell types. Topipotent stem cells are stem cells that have the potenti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0775C12N5/00A61K35/28A61K9/00
CPCC12N5/0031C12N5/0667C12N2501/24C12N2501/25A61K9/0048A61K47/10A61K47/12A61K47/14A61K47/183A61K47/22A61K47/26A61K9/06A61K9/08A61K9/10A61K9/19A61K35/28A61P27/02A01N1/0221A61K9/0019
Inventor R·S·冈嘉拉居N·M·J·索尔V·H·乔特兰德M·潘特寇斯特
Owner CELL CARE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap